Hepatoblastoma: Recent developments in research and treatment

Seminars in Pediatric Surgery

Volumn 21, Issue 1, 2012, Pages 21-30

  Von Schweinitz, Dietrich ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Hepatoblastoma; Molecular biology; Risk stratification; Surgery

Indexed keywords

ALPHA FETOPROTEIN; AMIFOSTINE; ANTINEOPLASTIC AGENT; AXIN; BETA CATENIN; BETULIC ACID; CARBOPLATIN; CISPLATIN; CYCLOPAMINE; DOXORUBICIN; EPIGALLOCATECHIN GALLATE; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; IRINOTECAN; MELPHALAN; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIRARUBICIN; PROTEIN BCL 2; PROTEIN KINASE B; RAPAMYCIN; SCATTER FACTOR; SODIUM THIOSULFATE; SOMATOMEDIN B; SONIC HEDGEHOG PROTEIN; SORAFENIB; TRASTUZUMAB; VINCRISTINE; WNT1 PROTEIN;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILDHOOD CANCER; CHROMOSOME DELETION; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; EVENT FREE SURVIVAL; GENE MUTATION; HEPATOBLASTOMA; HISTOLOGY; HUMAN; LIVER TRANSPLANTATION; MEDICAL RESEARCH; METASTASIS; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STEM CELL; TUMOR BIOPSY; UNSPECIFIED SIDE EFFECT;

CHILD, PRESCHOOL; CISPLATIN; HEPATOBLASTOMA; HUMANS; INFANT; LIVER NEOPLASMS;

EID: 84855902014     PISSN: 10558586     EISSN: 15329453     Source Type: Journal    
DOI: 10.1053/j.sempedsurg.2011.10.011     Document Type: Article

References (45)

1. Meyers R.L., Aronson D.C., von Schweinitz D., et al. Pediatric liver tumors. Principles and Practice in Pediatric Oncology 2011, 838-860. Wolters Kluwer, Lippincott. Williams Wilkins, Philadelphia, PA. P.A. Pizzo, D.G. Poplack (Eds.).
2. Pediatric Liver Tumors 2011, Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
3. McLaughlin C.C., Baptiste M.S., Schymura M.J., et al. Maternal and infant birth characteristics and hepatoblastoma. Am J Epidemiol 2006, 163:818-828.
4. Birch J.M. Epidemiology of pediatric liver tumors. Pediatric Liver Tumors 2011, 15-26. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
5. Zimmermann A. Ontogenetic aspects of liver tumors. Pediatric Liver Tumors 2011, 43-51. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
6. Zimmermann A., Lopez-Terrada D. Pathology of pediatric liver tumors. Pediatric Liver Tumors 2011, 83-112. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
7. Zimmermann A. The emerging family of hepatoblastoma tumours: From ontogenesis to oncogenesis. Eur J Cancer 2005, 41:1503-1514.
8. Trobaugh-Lotrario A.D., Tomlinson G.E., Finegold M.J., et al. Small cell undifferentiated variant of hepatoblastoma: Adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer 2009, 52:328-334.
9. von Schweinitz D. Management of liver tumors in childhood. Semin Pediatr Surg 2006, 15:17-24.
10. Wang L.L., Filippi R.Z., Zurakowski D., et al. Effects of neoadjuvant chemotherapy on hepatoblastoma: A morphologic and immunohistochemical study. Am J Surg Pathol 2010, 34:287-299.
11. Kappler R., von Schweinitz D. Molecular aspects of hepatoblastoma. Pediatric Liver Tumors 2011, 27-42. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
12. Arai Y., Honda S., Haruta M., et al. Genome-wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplificatiopn at 1q32.1 in hepatoblastoma. Genes Chrom Cancer 2010, 49:596-609.
13. Li Y.C., Deng Y.H., Guo Z.H., et al. Prognostic value of hedgehog signal component expressions in hepatoblastoma patients. Eur J Med Res 2010, 15:468-474.
14. Pietsch T., Steiger B., Leuschner I., et al. Expression and function of the receptor tyrosine kinase erbB2 in hepatoblastomas. Monatsschr Kinderheilkd 2011, 159:400.
15. Litten J., Chen T., Schultz R., et al. Activated NOTCH2 is overexpressed in hepatoblastomas: An immunohistochemical study. Pediatr Dev Pathol 2011, Epub ahead of print.
16. Turato C., Buendia M.A., Fabre M., et al. Over-expression of SERPINB3 in hepatoblastoma: A possible insight into the genesis of this tumour?. Eur J Cancer 2011, Epub ahead of print.
17. Von Frowein J., Pagel P., Kappler R., et al. MicroRNA-492 is processed from the keratin 19 gene and up-regulated in metastatic hepatoblastoma. Hepatology 2011, 53:833-842.
18. Cairo S., Armengol C., De Reyniès A., et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008, 14:471-484.
19. Franzius C. FDG-PET/CT in pediatric solid tumors. Q J Nucl Med Mol Imaging 2010, 54:401-410.
20. Roebuck D.J. Imaging and staging of pediatric liver tumors. Pediatric Liver Tumors 2011, 65-82. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
21. Roebuck D.J., Aronson D.C., Clapuyt P., et al. PRETEXT: A revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 2005, 2007:123-132.
22. Malogolowkin M.H., Katzenstein H.M., Meyers R.L., et al. Complete surgical resection is curative for children with hepatoblastoma with pure fetal histology: A report from the Children's Oncology Group. J Clin Oncol 2011, 29:3301-3306.
23. Hishiki T., Matsunaga T., Sasaki F., et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Tumor (JPLT) protocol 2: Report from the JPLT. Pediatr Surg Int 2011, 27:1-8.
24. Czauderna P., von Schweinitz D. Surgical treatment. Pediatric Liver Tumors 2011, 113-132. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
25. Guérin F., Gauthier F., Martelli H., et al. Outcome of central hepatectomy for hepatoblastomas. J Pediatr Surg 2010, 45:555-563.
26. Lautz T.B., Ben-Ami T., Tantemsapya N., et al. Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma. Cancer 2011, 117:1976-1983.
27. Meyers R.L., Otte J.-B. Liver transplantation for unresectable liver tumors in children. Pediatric Liver Tumors 2011, 113-152. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
28. Gupta A.A., Gerstle J.T., Ng V., et al. Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatr Blood Cancer 2011, 56:1013-1018.
29. Haeberle B., Schmid I., von Schweinitz D. Is there a very high risk group in childhood hepatoblastoma?. A subgroup analysis of the GPOH study HB99. Pediatr Blood Cancer 2010, 55:815.
30. Otte J.B., Meyers R. PLUTO first report. Pediatr Transplant 2010, 14:830-835.
31. Perilongo G., Morland B., Malogolowkin M. Chemotherapy for childhood hepatoblastoma and hepatocellular carcinoma. Pediatric Liver Tumors 2011, 153-164. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
32. Perilongo G., Maibach R., Shafford E., et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med 2009, 361:1662-1670.
33. Zsiros J., Brock P., Brugières L., et al. High cure rate in high risk hepatoblastoma with dose intensive cisplatin based chemotherapy-Results of the SIOPEL-4 trial. Pediatr Blood Cancer 2010, 55:816.
34. Zsiros J., Maibach R., Shafford E., et al. Successful treatment of childhood high-risk hepatoblastoma with dose-intensive multiagent chemotherapy and surgery: Final results of the SIOPEL-3HR study. J Clin Oncol 2010, 28:2584-2590.
35. Zsiros J., Brugieres L. Salvage strategies. Pediatric Liver Tumors 2011, 165-176. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
36. Beaty O., Berg S., Blaney S., et al. A phase II trial and pharmacokinetic study of oxaliplatin in children with refractory solid tumors: A Children's Oncology Group study. Pediatr Blood Cancer 2010, 55:440-445.
37. Neuwelt A.J., Wu Y.J., Knap N., et al. Using acetaminophen's toxicity mechanism to enhance cisplatin efficacy in hepatocarcinoma and hepatoblastoma cell lines. Neoplasia 2009, 11:1003-1011.
38. Qayed M., Powell C., Morgan E.R., et al. Irinotecan as maintenance therapy in high-risk hepatoblastoma. Pediatr Blood Cancer 2010, 54:761-763.
39. Schmid I., Haeberle B., Corbacioglu S., et al. First experience with sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr Blood Cancer 2011, Epub ahead of print.
40. Takahashi-Yanaga F., Kahn M. Targeting Wnt signaling: Can we safely eradicate cancer stem cells?. Clin Cancer Res 2010, 16:3153-3162.
41. Ng J.M., Curran T. The Hedgehog's tale: Developing strategies for targeting cancer. Nat Rev Cancer 2011, 11:493-501.
42. Aktas S., Zadeoglulari Z., Ercetin P., et al. The effect of differentiating and apoptotic agents on notch signalling pathway in hepatoblastoma. Hepato Gastroenterol 2010, 57:891-898.
43. Lieber J., Eicher C., Wenz J., et al. The BH13 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma. BMC Cancer 2011, 11:362.
44. Roebuck D.J. Alternative approaches for treatment. Pediatric Liver Tumors 2011, 177-188. Springer, Heidelberg. A. Zimmermann, G. Perilongo, M. Malogolowkin, D. von Schweinitz (Eds.).
45. De Ioris M., Brugières l., Zimmermann A., et al. Hepatoblastoma with a low serum alpha-fetoprotein level at diagnosis: The SIOPEL group experience. Eur J Cancer 2008, 44:545-550.